Novosteo Inc., a West Lafayette, Ind.-based startup developing fracture-targeted bone anabolic agents intended to selectively accumulate on the bone fracture surface to accelerate healing, has won a $1.7 million SBIR phase I/II grant from the NIH. The grant is expected to help the Purdue University-affiliated company with testing and preparation for phase I trials.